Previous 10 | Next 10 |
Passage Bio, Inc. (PASG) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Stuart Henderson - Vice President of Corporate Development and Investor Relations Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - Ch...
The following slide deck was published by Passage Bio, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Passage Bio, Inc. 2022 Q1 - Results - Earnings Call Presentation
Passage Bio press release (NASDAQ:PASG): Q1 GAAP EPS of -$0.79 beats by $0.09. Cash, cash equivalents and marketable securities were $267.1M. “We are thrilled to have recently submitted an IND for PBML04 in metachromatic leukodystrophy, our third rare, pediatric, lysosomal storag...
Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22 Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; inter...
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ...
Gainers: REGENXBIO (RGNX) +8%. Passage Bio (PASG) +6%. Yellow Corporation (YELL) +6%. Fluence Energy (FLNC) +6%. Fate Therapeutics (FATE) +4%. Losers: Cytokinetics (CYTK) -5%. Golden Entertainment GDEN -5%. AlloVir (ALVR) -5%. Arcimoto (FUV) -4%. Canaan (CAN) -...
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in...
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Not long ago, PASG was awarded a $1.2B enterprise value by the market. Though the company made progress, the vagaries of the market are such that it now trades at a negative enterprise value. I survey the company and its programs to find reasons to monitor its progress with the po...
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...